Filament Health

A clinical-stage natural psychedelic drug development company. $FLHLF $7QS

[SpencerHawkswell @SpencerHawkswe1]

Today, @TheraPsil alongside @SabiMind and @FilamentHealth launched the first wellness-focused & stakeholder-funded psilocybin clinical trial.

Psychedelic research is about to change.

See full release here: https://t.co/TjytpuMEe3

[Mugglehead Magazine @MuggleheadMag]

.@FilamentHealth has received FDA approval for another clinical trial on its lead drug candidate PEX010.

$FLHLF #psilocybin #Veterans #psychedelics

https://t.co/9V2Q6MEoim

[Filament Health @FilamentHealth]

Today we announced positive data from a phase 2 study of PEX010 in patients with alcohol use disorder. The study found that after 1 dose of #psilocybin, the mean % of heavy drinking days was reduced by more than 50% over the 12-week observation period.

https://t.co/AtolciQ98u

[Daniel S. Levine @dslevine]

.@benlightburn @FilamentHealth discusses the company’s approach to psychedelic medicine, the case for natural botanical extracts rather than synthetic compounds, and its lead experimental therapy that targets methamphetamine use disorder.

https://t.co/SVSAkmmoM2

[Filament Health @FilamentHealth]

Today we announced the import of Peruvian coca leaf to our Vancouver R&D facility for the development of a botanical drug candidate to treat ADHD.

https://t.co/AHE8nHaIOw

[Filament Health @FilamentHealth]

We're proud to supply our botanical psilocybin drug candidate for this much-needed research into opioid use disorder at @imperialcollege.

[Imperial Department of Brain Sciences @ImperialBrains]

A groundbreaking clinical trial will explore the use of psilocybin, the active compound in magic mushrooms, to combat opioid addiction. 🍄

This ‘first in the UK’ study aims to help prevent relapse with the power of psychedelics and psychological support.
https://t.co/F7vMXxmNcq

[Filament Health @FilamentHealth]

Today we announced a major expansion of our IP portfolio, with 12 new patents accepted in Australia, 5 in Canada, & 3 in the US. Filament holds a total of 46 allowed patents relating to the development & delivery of naturally-derived psychedelic APIs.

https://t.co/0SRNI414sn

[Filament Health @FilamentHealth]

Today we announced authorization by both @US_FDA & @GovCanHealth of a Phase 2 clinical trial studying PEX010 for methamphetamine use disorder. This is the first ever clinical trial to study the safety & efficacy of botanical #psilocybin for MAUD.

https://t.co/YMZFyVYmgS

[Filament Health @FilamentHealth]

We're pleased to report our Q1 2024 results, including important advancement of our drug development efforts in substance use disorders.

https://t.co/yVSoY5QhS2

[Filament Health @FilamentHealth]

Our CEO @benlightburn will be hosting an #AMA with @ceodotca at 12PM ET tomorrow to discuss our latest news and developments. Submit questions for Ben via: https://t.co/6s2BwB1nLm

[Filament Health @FilamentHealth]

We're pleased to report our 2023 year-end results including $2.1 million in revenue + @GovCanHealth approval of a Filament-sponsored Phase 2 clinical trial studying our botanical psilocybin for opioid use disorder at @UBC.

https://t.co/k7cM8mHHyZ

[Filament Health @FilamentHealth]

We're pleased to announce that Michael Messinger has been appointed to our Board of Directors, bringing over 20 years' experience in biotech finance roles.

https://t.co/NcL1bDmCIG

[Water Tower Research LLC @WTR_Research]

Join Robert Sassoon for a fireside chat with @FilamentHealth CEO Ben Lightburn on Thursday, April 4th, at 12:00 pm ET.
#psychedelics #psychedelictherapy #therapeutics
https://t.co/GwZGbkKiip

[Filament Health @FilamentHealth]

Read about @UCalgary's upcoming study which will examine the effects of our botanical #psilocybin for alcohol use disorder:

[High Times @HIGH_TIMES_Mag]

Can the power of magic mushrooms overcome the pull of alcohol use disorder? 🍄🍻

An upcoming study based in Canada aims to shed light on the potential for psilocybin’s role in battling the beast that is alcohol addiction. https://t.co/sZStp3CnJx

[Mugglehead Magazine @MuggleheadMag]

The @UCalgary is about to start a major study on psilocybin-assisted therapy for the treatment of alcoholism.

British Columbia’s @FilamentHealth will provide magic mushroom extract needed for the research.

$FLHLF #psychedelics #psilocybin

https://t.co/k5b35IpIxS

[Filament Health @FilamentHealth]

We're proud to supply our botanical psilocybin for this important research at @UCalgary:

[Calgary Herald @calgaryherald]

Mushrooms' potential magic in quelling alcohol abuse the focus of U of C researchers #yyc https://t.co/FFtr2Y2rts

[Filament Health @FilamentHealth]

Today we announced that we have shipped our botanical psilocybin drug candidate, PEX010, to 4 countries for clinical trials at leading research institutions including @JohnsHopkins.

https://t.co/AhuauZWQFt

[Filament Health @FilamentHealth]

Could psilocybin offer a solution to the opioid crisis? We take a look in our latest blog post:

https://t.co/bWXWqhOv2B

[MindForward @mndfrwrd2]

2024 is set to be a watershed year for #Psychedelics.
Alongside an influx of biotech investment in the UK, the industry has seen significant milestones set to accelerate the sector, return confidence & advance #MentalHealth innovations.

Find out more. 👇
https://t.co/Zq1c2V8IIp

[Filament Health @FilamentHealth]

"We developed specific technology that has allowed us to create the first & only pharmaceutical grade natural psychedelic drug candidates." - CEO @benlightburn spoke to @PharmExec Magazine about our novel approach to psychedelic drug development.

https://t.co/ZGWZsajkic